Ardelyx Inc
NASDAQ:ARDX

  • LAST PRICE
    6.9000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 6.9000
  • Day Range
    ---
  • 52 Week Range
    3.1600
    10.1300
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ARDX
Ardelyx Inc
1.6B
-23.9x
---
RCUS
Arcus Biosciences Inc
1.5B
-5.1x
---
VIR
Vir Biotechnology Inc
1.4B
-2.7x
---
XNCR
Xencor Inc
1.5B
-10.7x
---
PTGX
Protagonist Therapeutics Inc
1.8B
12.2x
---
GYRE
Gyre Therapeutics Inc
1.0B
-5.4x
---
As of 2024-05-29

Company Information

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Contact Information

Headquarters
34175 Ardenwood BlvdFREMONT, CA, United States 94555-3653
Phone
510-745-7047
Fax
510-745-0493

Executives

Independent Chairman of the Board
David Mott
President, Chief Executive Officer, Director
Michael Raab
Chief Financial Officer
Justin Renz
Chief Legal and Administrative Officer
Elizabeth Grammer
Chief Regulatory Affairs and Quality Assurance Officer
Robert Blanks

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.6B
Revenue (TTM)
$159.1M
Shares Outstanding
234.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.78
EPS
$-0.29
Book Value
$0.72
P/E Ratio
-23.9x
Price/Sales (TTM)
10.1
Price/Cash Flow (TTM)
---
Operating Margin
-38.90%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.